This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related letter  • Related article  • Similar articles in this journal  Topic Collections  • Pediatrics  • Bipolar Disorder  • Depression  • Mood Disorders  • Psychopharmacology  • Women's Health  • Pregnancy and Breast Feeding  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic

Tim F. Oberlander, MD, FRCPC; William Warburton, PhD; Shaila Misri, MD, FRCPC; Jaafar Aghajanian, BSc; Clyde Hertzman, MD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In reply

We note with interest comments by Einarson et al and Olfson and Marcus. Einarson et al raised questions about the Abstract. We believe that the Abstract is consistent with data presented in the article, and specific details were omitted because of space limitations. In response to the questions raised, we offer the following comments:

First, the rates of small for gestational age (SGA) in our sample may have been lower than what would have been expected for a population; this, however, should not invalidate or detract from our findings that the proportion of propensity score–matched infants of depressed mothers treated with SSRIs was significantly greater than for infants of mothers in the depressed or control groups. We used an American standard reference for SGA¹ and our sample from British Columbia . . . [Full Text of this Article]

AUTHOR INFORMATION

RELATED LETTER

Neonatal Risks of Maternal Treatment With Mood Stabilizers
Mark Olfson and Steven Marcus
Arch Gen Psychiatry. 2007;64(7):866-867.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Neonatal Risks of Maternal Treatment With Mood Stabilizers
Mark Olfson and Steven Marcus
Arch Gen Psychiatry. 2007;64(7):866-867.
EXTRACT | FULL TEXT